Viewing Study NCT00626704

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 8:00 PM
Ignite Modification Date: 2026-04-08 @ 5:52 AM
Study NCT ID: NCT00626704
Status: COMPLETED
Last Update Posted: 2015-05-25
First Post: 2008-02-14
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma
Sponsor: Amgen
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma View
None Sarcoma View
None Soft Tissue Sarcoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Sarcoma View
None Soft Tissue Sarcoma View
None Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma View
None AMG 655 View
None STS View
None Doxorubicin View
None Death receptor View
None TRAIL receptor View
None Apoptosis View